The use of quaternary pyridinium salts as vasoprotective agents

Details for Australian Patent Application No. 2005205066 (hide)

Owner Pharmena SA

Inventors Chlopicki, Stefan; Gebicki, Jerzy

Agent Davies Collison Cave

Pub. Number AU-B-2005205066

PCT Pub. Number WO2005/067927

Priority P-364348 12.01.04 PL

Filing date 7 January 2005

Wipo publication date 28 July 2005

Acceptance publication date 29 April 2010

International Classifications

A61K 31/4425 (2006.01) - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine

Event Publications

24 August 2006 PCT application entered the National Phase

  PCT publication WO2005/067927 Priority application(s): WO2005/067927

30 October 2008 Alteration of Name

  The name of the applicant has been altered to Pharmena SA Amendments

29 April 2010 Application Accepted

  Published as AU-B-2005205066

6 May 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 15 Apr 2010. Address for service in Australia - Davies Collison Cave 255 Elizabeth Street Sydney NSW 2000

26 August 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 15 Apr 2010

2 September 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005205067-Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neurodegenerative disorders

2005205064-Use of metal complex compounds as catalysts for oxidations with peroxy acids and/or precursors of organic peroxy acid and H2O2